Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Cancer- and cancer treatment-related conditions
Stage/Subtype:  graft versus host disease
Trial Type:  Supportive care
Trial Status:  Active
Sponsor of Trial:  NCI
Results 1-25 of 26 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Phase: Phase III
Type: Supportive care
Status: Active
Age: 70 and under
Sponsor: NCI, Other
Protocol IDs: CASE6Z13, NCI-2013-01800, P30CA043703, NCT01951885
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: 040055, 04-C-0055, NCI-04-C-0055, NCT00077480, NCT00074490
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 2206.00, NCI-2010-02222, P30CA015704, P01CA018029, NCT01251575
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Phase: Phase II
Type: Supportive care
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 2545.00, NCI-2011-03827, P30CA015704, R01HL108307, NCT01525407
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 0 to 75
Sponsor: NCI, Other
Protocol IDs: 2546.00, NCI-2011-03828, P30CA015704, P01CA018029, NCT01527045
Clobetasol for Oral Graft-Versus-Host Disease
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 12 to 99
Sponsor: NCI
Protocol IDs: 120068, 12-C-0068, NCT01557517
Pomalidomide for Chronic Graft-versus-Host Disease
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: 120197, 12-C-0197, NCT01688466
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2661.00, NCI-2013-00538, 2661, P30CA015704, NCT01812252
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: 2660.00, NCI-2013-00958, K23CA154532, P30CA015704, NCT01858740
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
Phase: Phase II
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 18 to less than 70
Sponsor: NCI, Other
Protocol IDs: 2013LS091, MT2013-27, P01CA065493, NCT02118311
Tocilizumab for Chronic Graft-versus-Host Disease Treatment
Phase: Phase II
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 9130, NCI-2014-01204, P30CA015704, NCT02174263
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Phase: Phase II
Type: Supportive care
Status: Active
Age: 18 to 75
Sponsor: NCI, NHLBI
Protocol IDs: BMTCTN1203, U01HL069294, NCT02208037
Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD
Phase: Phase II
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 150039, 15-C-0039, NCT02322190
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Phase: Phase II
Type: Supportive care
Status: Approved-not yet active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: 13494, NCI-2015-00283, R01CA181045, NCT02396134
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Phase: Phase I
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: BMT243, NCI-2012-00044, SU-01272012-9028, 22626, NCT01523223
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 9L-11-8, NCI-2013-00447, NCT01801046
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 13-281, R01CA183559-01, NCT01937468
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: CASE1A13, NCI-2013-01777, P30CA043703, NCT01954784
Low-Dose Total Lymphoid Irradiation in Treating Patients With Refractory Chronic Graft-versus-Host Disease After Donor Stem Cell Transplant
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CCCWFU 97114, NCI-2014-00671, P30CA012197, NCT02109809
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CASE9Z13, NCI-2014-00837, P30CA043703, NCT02129582
Neihulizumab in Treating Patients With Steroid Refractory Acute Graft-versus-Host Disease After Donor Stem Cell Transplant
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: BMT285, NCI-2015-00631, IRB-32842, 348, P30CA124435, NCT02436460
Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: VICC BMT 1063, NCI-2011-00225, NCT01324908
Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 021202, NCI-2013-00094, Pro2012001625, P30CA072720, NCT02144701
Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 and older
Sponsor: NCI, Other
Protocol IDs: 021309, NCI-2014-01411, P30CA072720, Pro2014004116, NCT02203578
Start Over